Novartis has stockpiles to withstand potential Trump tariffs, CEO says

Core Viewpoint - Novartis has proactively increased its stockpiles of pharmaceuticals in the United States to mitigate potential impacts from President Donald Trump's tariffs on its products [1] Company Summary - The chief executive of Novartis indicated that the company is well prepared for any adverse effects that may arise from the tariffs imposed by the U.S. government [1]